TRACON Pharmaceuticals Inc (NASDAQ: TCON) Stock In Prove Me State

TRACON Pharmaceuticals Inc (TCON) concluded trading on Wednesday at a closing price of $0.22, with 16.89 million shares of worth about $3.72 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 31.59% during that period and on April 3, 2024 the price saw a loss of about -47.18%. Currently the company’s common shares owned by public are about 44.27M shares, out of which, 40.26M shares are available for trading.

Stock saw a price change of -48.95% in past 5 days and over the past one month there was a price change of 16.45%. Year-to-date (YTD), TCON shares are showing a performance of 25.36% which decreased to -88.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $2.14 during that period. The average intraday trading volume for TRACON Pharmaceuticals Inc shares is 2.98 million. The stock is currently trading -41.94% below its 20-day simple moving average (SMA20), while that difference is down -16.84% for SMA50 and it goes to -8.02% lower than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

TRACON Pharmaceuticals Inc (NASDAQ: TCON) currently have 44.27M outstanding shares and institutions hold larger chunk of about 11.23% of that.

The stock has a current market capitalization of $9.99M and its 3Y-monthly beta is at 1.04. It has posted earnings per share of -$0.26 in the same period. It has Quick Ratio of 0.89. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TCON, volatility over the week remained 31.56% while standing at 30.45% over the month.

Stock’s fiscal year EPS is expected to drop by -115.15% while it is estimated to increase by 23.94% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on April 16, 2021 offering a Buy rating for the stock and assigned a target price of $14 to it. Coverage by Maxim Group stated TRACON Pharmaceuticals Inc (TCON) stock as a Buy in their note to investors on February 10, 2021, suggesting a price target of $24 for the stock. On December 23, 2019, H.C. Wainwright Reiterated their recommendations, while on March 01, 2019, Needham Reiterated their ratings for the stock with a price target of $7. Stock get a Buy rating from Stifel on June 13, 2017.

Most Popular

Related Posts